Title

Pemigatinib-induced nail changes - A case report

Affiliations

Aurora BayCare Medical Center

Abstract

INTRODUCTION: Pemigatinib is an FGFR inhibitor that is one of few second-line treatment options for cholangiocarcinoma. Nail toxicities were common in the phase 2 study evaluating the safety and efficacy of pemigatinib.

CASE REPORT: We describe a 54-year-old female with a history of stage IV cholangiocarcinoma presenting for a follow-up visit after completing Cycle 4 of pemigatinib. The patient had been having significant nail changes to her fingernails and toenails, which has led to her great toenails falling off.

DISCUSSION: Nail changes are a common side effect with pemigatinib and should be monitored closely for the need for temporary disruption in therapy.

Document Type

Case Report

PubMed ID

33736556

Link to Full Text

 

Share

COinS